According to the collaboration partners, evidence shows that most cancers take years or even decades to develop from normal cells to precancerous cells (or precancer) to cancer. Oxford University has very strong expertise in the study of precancer biology including the identification and sequencing of neoantigens, or tumor-specific proteins that prompt the immune system to recognize cancer. This unique focus could help target the vulnerabilities of precancerous cells through an active intervention like a vaccine or targeted medicine to prevent them from progressing to cancer.

Tony Wood, GSK’s chief scientific officer, said: “We’re pleased to further strengthen our relationship with Oxford University and to combine the deep knowledge of Oxford and GSK scientists. By exploring precancer biology and building on GSK’s expertise in the science of the immune system, we aim to generate key insights for people at risk of developing cancer.”

Irene Tracey, vice-chancellor of the University of Oxford, commented: “This partnership represents a step forward in cancer research. By working with GSK to unite experts in clinical trials, immuno-oncology, vaccinology and precancer research from across the University of Oxford, we aim to unlock the potential of cancer vaccines and bring hope to patients worldwide.”

Building on GSK’s ongoing relationship with Oxford, this collaboration intends to continue to combine the British pharma company’s expertise in the science of the immune system and global development capability with Oxford’s cutting-edge research and clinical capabilities.

In 2021, GSK and Oxford University established the Institute of Molecular and Computational Medicine. Located at the University of Oxford, it has made progress in improving the success and speed of drug discovery and development, particularly in the field of neurodegeneration, by building on insights from human genetics and using technologies such as functional genomics and machine learning.